Paul Dillon
- Toxicology top 0.1%
- Forensic Toxicology and Drug Analysis 13
- Pharmacology top 1%
- Cannabis and Cannabinoid Research 8
- Hepatology top 2%
- Biological Psychiatry top 5%
- Family Practice top 5%
- Medication Adherence and Compliance 7
-
- Substance Abuse Treatment and Outcomes 12
-
- Psychedelics and Drug Studies 8
-
- Hormonal and reproductive studies 7
-
- Blood Pressure and Hypertension Studies 6
-
- Pharmaceutical Practices and Patient Outcomes 5
- Co-authors
- Jan CopelandPeter GatesLouisa DegenhardtMark A BellisKaren HughesWendy SwiftД. А. ШапироJulie Hando
- Cited by
- ToxicologyPharmacologyHepatology
- Journals
- Addiction (4 papers)Drug and Alcohol Dependence (4 papers)Drug and Alcohol Review (3 papers)
- Partner nations
- AustraliaIrelandUnited States
In The Last Decade
Paul Dillon
68 papers receiving 3.2k citations
Hit Papers
Peers
Comparison fields: 5 of 169
- Toxicology 673
- Pharmacology 786
- Hepatology 315
- Biological Psychiatry 98
- Family Practice 80
Countries citing papers authored by Paul Dillon
This map shows the geographic impact of Paul Dillon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Dillon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Dillon more than expected).
Fields of papers citing papers by Paul Dillon
This network shows the impact of papers produced by Paul Dillon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Dillon. The network helps show where Paul Dillon may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Paul Dillon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 2 | |
| 2 | 2023 | 0 | |
| 3 | 2022 | 75 | |
| 4 | 2020 | 54 | |
| 5 | A real-world data study of coronavirus-2019 disease severity in patients with multiple sclerosis treated with ocrelizumab | 2020 | 2 |
| 6 | 2019 | 12 | |
| 7 | 2019 | 5 | |
| 8 | Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Diseasebreakdown → | 2013 | 767 |
| 9 | 2011 | 20 | |
| 10 | 2011 | 16 | |
| 11 | 2010 | 18 | |
| 12 | 2010 | 84 | |
| 13 | A NEW THERAPY FOR NONALCOHOLIC FATTY LIVER DISEASE AND DIABETES? INT-747-THE FIRST FXR HEPATIC THERAPEUTIC STUDY | 2009 | 18 |
| 14 | 2008 | 67 | |
| 15 | 2007 | 21 | |
| 16 | 2007 | 30 | |
| 17 | 2005 | 95 | |
| 18 | 2003 | 69 | |
| 19 | 2002 | 112 | |
| 20 | 1983 | 0 |
About Paul Dillon
Paul Dillon is a scholar working on Toxicology, Family Practice, Geriatrics and Gerontology, Biological Psychiatry and Pharmacology, having authored 71 papers that have together received 3.3k indexed citations. Recurring topics across this work include Forensic Toxicology and Drug Analysis (13 papers), Substance Abuse Treatment and Outcomes (12 papers), Psychedelics and Drug Studies (8 papers), Cannabis and Cannabinoid Research (8 papers), Hormonal and reproductive studies (7 papers), Medication Adherence and Compliance (7 papers), Blood Pressure and Hypertension Studies (6 papers) and Pharmaceutical Practices and Patient Outcomes (5 papers). The work is most often cited by research in Toxicology (673 citations), Pharmacology (786 citations), Hepatology (315 citations), Biological Psychiatry (98 citations) and Family Practice (80 citations). Paul Dillon has collaborated with scholars based in Australia, Ireland and United States. Frequent co-authors include Jan Copeland, Peter Gates, Louisa Degenhardt, Mark A Bellis, Karen Hughes, Wendy Swift, Д. А. Шапиро, Julie Hando, Mark Kipnes and Paul Clopton. Their work appears in journals such as Addiction, Drug and Alcohol Dependence, Drug and Alcohol Review, International Journal of Drug Policy and Multiple Sclerosis and Related Disorders.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.